Efficacy of galantamine on cognitive performance

Phase 3

• Conditions: Condition 1: Schizophrenia. Condition 2: Schizoaffective. Condition 3: Mood disorders. Condition 4: Obsessive- compulsive disorders.; Schizophrenia; Schizoaffective disorders; Mood disorder due to known physiological condition with mixed features; Obsessive-compulsive disorder; F06.34

• Registration Number: IRCT20200207046404N1
• Lead Sponsor: Sanandaj University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 75

Inclusion Criteria

Patients aged between 18-60 years
Patients or their legal guardian must sign an informed consent form
Number of sessions of ECT between 4-8

Exclusion Criteria

Alcohol & drug abuse or dependence
Renal failure
Ischemic heart disease
Stroke in last 6 months
Delirium &Dementia
Pregnancy & Lactation
History of using Galantamine in past 3 months
Galantamine sensitivity
Mental retardation

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Memory. Timepoint: 1day before begining and after session 3 and after the electroconvulsive therapy. Method of measurement: Wechsler, mini mental statuse examination.

Secondary Outcome Measures

Name	Time	Method
ausea. Timepoint: During intervention( once a day for 15 days). Method of measurement: Patient self report.;Confusion. Timepoint: During intervention(once a day for 15 days). Method of measurement: Patient self report.;Dizziness. Timepoint: During intervention(once a day for 15 days). Method of measurement: Patient self report.